Elanco Animal Health (NYSE:ELAN) Given New $14.00 Price Target at Morgan Stanley

Elanco Animal Health (NYSE:ELAN) had its target price trimmed by Morgan Stanley from $15.00 to $14.00 in a report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other analysts also recently commented on ELAN. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. UBS Group began coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. Stifel Nicolaus reduced their target price on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays upped their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Finally, Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Trading Up 1.0 %

NYSE ELAN opened at $12.30 on Wednesday. The firm has a market capitalization of $6.08 billion, a PE ratio of 30.74, a price-to-earnings-growth ratio of 2.57 and a beta of 1.41. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The business’s 50-day moving average price is $12.24 and its two-hundred day moving average price is $13.25. Elanco Animal Health has a 12 month low of $11.11 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.18 EPS. On average, analysts expect that Elanco Animal Health will post 0.92 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors have recently made changes to their positions in ELAN. ORG Wealth Partners LLC purchased a new stake in shares of Elanco Animal Health during the third quarter worth $29,000. AM Squared Ltd purchased a new stake in shares of Elanco Animal Health in the third quarter worth $34,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health in the third quarter worth $35,000. Quarry LP purchased a new stake in shares of Elanco Animal Health in the second quarter worth $40,000. Finally, Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after buying an additional 2,044 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.